- < General Internal Medicine
First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial
By sjmartinez • January 23, 2025
Shen L, Zhang Y, Li Z, Zhang X, Gao X, Liu B, Wang Y, Ba Y, Li N, Zhang R, Zhang J, Chen Y, Chen J, Huang M, Fu Y, Liu M, Liu Z, Zhao J, Li W, Wei J, Li C, Xu N, Guo Z, Cao B, Liu L, Nie P, Wan L, Sheng L, Liu Z, He Y, Gu K, Wu G, Wang W, Zhang F, Qiu W, Guo J, Ying J, Pan H, Xu H, Yuan Y, Bai Y, Wang Z, Xu J, Zhao X, Liu H, Zhang X, Dai W, Xu H, Liu M, Xie L, Tang Y, Jin J, Qu X, Fang X, Huang M, Chen H, Zheng Z, Wang Y, Wang D, Li X, Yu G, Liu H, Zhou Y, Zhong D, Zeng S, Kang M, Wang M, Gao Y, Li W, Wang Z, Zhang M, Zhang J, Li Q, Sun S, Zang A, Lin L, Xie M, Zhuang Z, Zhang T, Yao Z, Lu D, Liu W, Hu M, Wang ZM, Li B, Xia M, Zhang J, Ying X, Pardoll DM, Ji J. First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial. Nat Med. 2025 Jan 22. doi: 10.1038/s41591-024-03450-4. Epub ahead of print. PMID: 39843940.
Related Posts
Narain K, Markovic D, Escarce JJ. A cross-sectional analysis of the association between self-employment, racial and ethnic minority status, sex and cardiovascular disease risk factors[...]
Anand S, Pasupneti T, Pak Y, Kalangi ST, Garg R. Differences in fat distribution between metabolically unhealthy people with normal weight versus obesity, NHANES 2011-2018.[...]
Brunyé TT, Shucard H, Eguchi MM, Drew T, Marotti J, Lomo LC, Kilgore MR, Allison KH, Kerr KF, Elmore JG, Weaver DL. Characterizing Interpretive and[...]
